Sonia Hernández-Díaz, MD, DrPH

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts

JCP
Atomoxetine and Prevalence of Major Congenital Malformations
Original Research

image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ January 16, 2023

Little is known about the safety of atomoxetine, a non-stimulant treatment for attention-deficit/hyperactivity disorder. This study assessed the prevalence of major congenital malformations after first-trimester exposure to atomoxetine.
Gabriella Bröms, Sonia Hernández-Díaz, Krista F. Huybrechts, et al
JCP
Correction

October 5, 2021

Adele C. Viguera, Marlene P. Freeman, Lina Góez-Mogollón, et al
JCP
Reproductive Safety of Second-Generation Antipsychotics
Original Research

August 3, 2021

What do data from a pregnancy registry demonstrate about the risk of major malformations among infants exposed to second-generation antipsychotics during the first trimester?
Adele C. Viguera, Marlene P. Freeman, Lina Góez-Mogollón, et al
JCP
Article

April 22, 2015

Lee S. Cohen, Adele C. Viguera, Kathryn A. McInerney, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe